MX
MXCT.LSE MaxCyte Inc
- Market cap
- GBX 162M
- P/E
- -
- P/B
- 1.16x
- ROE
- -23.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2025.
Is MXCT.LSE undervalued?
Graham numberThe Graham number of MaxCyte Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
MaxCyte Inc fundamental analysis
No fundamental analysis for MaxCyte Inc yet.
MaxCyte Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About MaxCyte Inc
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in thera…
Full company profileMaxCyte Inc financial statements
2025 annualized: Fiscal year 2025 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2025, the balance sheet is the latest quarter. Figures change when the annual report is published.
MaxCyte Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 9.29M | 12.3M | 14.0M | 16.7M | 21.6M | 26.2M | 33.9M | 44.3M | 41.3M | 38.6M | 37.8M |
| Gross Profit | 8.26M | 11.0M | 12.5M | 14.8M | 19.1M | 23.4M | 30.2M | 39.2M | 36.5M | 31.5M | 31.8M |
| Operating Income | -761K | -2.72M | -9.29M | -8.42M | -12.4M | -11.1M | -18.2M | -27.4M | -48.3M | -51.2M | -53.0M |
| EBITDA | -648K | -2.60M | -9.15M | -7.91M | -11.6M | -9.94M | -16.6M | -24.7M | -44.1M | -46.4M | -47.9M |
| Net Income | -1.45M | -3.35M | -9.92M | -9.31M | -13.6M | -12.6M | -20.1M | -19.8M | -37.9M | -41.1M | -45.2M |
| EPS | -0.76 | -0.10 | -0.20 | -0.18 | -0.24 | -0.18 | -0.22 | -0.19 | -0.37 | -0.39 | -0.43 |
| Balance Sheet | |||||||||||
| Total Assets | 6.40M | 16.1M | 31.4M | 24.3M | 30.0M | 51.8M | 284M | 287M | 268M | 239M | 220M |
| Total Liabilities | 9.48M | 11.0M | 11.8M | 12.0M | 16.4M | 18.6M | 21.2M | 32.7M | 36.1M | 33.2M | 29.0M |
| Shareholders' Equity | -3.08M | 5.08M | 19.6M | 12.3M | 13.6M | 33.2M | 263M | 254M | 232M | 206M | 191M |
| Cash & Short-term Investments | 2.41M | 11.7M | 25.3M | 14.4M | 16.7M | 34.8M | 255M | 227M | 168M | 154M | 127M |
| Total Debt | 5.04M | 5.01M | 5.03M | 5.06M | 7.21M | 6.97M | 5.68M | 16.1M | 18.7M | 18.0M | 18.5M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -181K | -2.34M | -9.68M | -10.5M | -8.80M | -8.78M | -10.7M | -14.8M | -21.7M | -27.6M | -48.5M |
| Capital Expenditure | 94.5K | 219K | 610K | 710K | 1.27M | 2.07M | 3.83M | 18.5M | 3.70M | 1.65M | 2.47M |
| Free Cash Flow | -275K | -2.55M | -10.3M | -11.2M | -10.1M | -10.9M | -14.5M | -33.3M | -25.4M | -29.3M | -51.0M |
| Ratios | |||||||||||
| ROE | - | -65.8% | -50.6% | -75.8% | -99.8% | -38.0% | -7.7% | -7.8% | -16.3% | -19.9% | -23.7% |
| ROA | -22.6% | -20.8% | -31.6% | -38.4% | -45.3% | -24.4% | -7.1% | -6.9% | -14.1% | -17.1% | -20.6% |
| Net Profit Margin | -15.6% | -27.3% | -70.9% | -55.9% | -62.8% | -48.3% | -59.4% | -44.7% | -91.8% | -106.3% | -119.7% |
| Debt to Equity | - | 0.98x | 0.26x | 0.41x | 0.53x | 0.21x | 0.02x | 0.06x | 0.08x | 0.09x | 0.10x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
MaxCyte Inc dividends
MaxCyte Inc has not paid dividends in the last 9 fiscal years.
Who owns MaxCyte Inc
- Insiders 1.45%
- Institutions 75.79%
- Public & others 22.76%
- Shares outstanding 106M
- Free float 95.1M
MaxCyte Inc company profile
- Company name
- MaxCyte Inc
- Ticker
- MXCT.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 114
- Fiscal year end
- December
- Address
- 9713 Key West Avenue, Rockville, MD, United States, 20850
- Phone
- 301 944 1700
- Website
- maxcyte.com
About MaxCyte Inc
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
MaxCyte Inc management
10- Mr. Maher MasoudPresident, CEO & Executive Director · born 1975
- Mr. Douglas J. Swirsky CFA, CPAChief Financial Officer · born 1969
- Mr. Ali SoleymannezhadChief Commercial Officer · born 1981
- Mr. Douglas Arthur DoerflerFounder · born 1956
- Mr. Jay GelfmanSenior Vice President of Operations
- Mr. Ronald Evan Holtz CPA, Ph.D.Executive Vice President of Administration · born 1958
- Mr. David SandovalSenior Vice President, General Counsel & Corporate Secretary · born 1978
- Mr. Jack HorganVice President of Corporate Development
- Ms. Ana-Paula Martins FernandesSenior Vice President of Global Sales
- Ms. Jill MayerSenior Vice President of Human Resources